company background image
A220100 logo

FutureChemLtd KOSDAQ:A220100 Stock Report

Last Price

₩21.60k

Market Cap

₩477.3b

7D

-11.5%

1Y

76.9%

Updated

08 Sep, 2024

Data

Company Financials

FutureChem Co.,Ltd

KOSDAQ:A220100 Stock Report

Market Cap: ₩477.3b

A220100 Stock Overview

Produces and sells radiopharmaceuticals in Korea.

A220100 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

FutureChem Co.,Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for FutureChemLtd
Historical stock prices
Current Share Price₩21,600.00
52 Week High₩25,650.00
52 Week Low₩7,690.00
Beta1.2
11 Month Change5.37%
3 Month Change38.11%
1 Year Change76.90%
33 Year Change51.78%
5 Year Change157.22%
Change since IPO204.94%

Recent News & Updates

FutureChem Co.,Ltd's (KOSDAQ:220100) 29% Share Price Surge Not Quite Adding Up

Sep 04
FutureChem Co.,Ltd's (KOSDAQ:220100) 29% Share Price Surge Not Quite Adding Up

FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans

Jun 13
FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans

FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Apr 29
FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Recent updates

FutureChem Co.,Ltd's (KOSDAQ:220100) 29% Share Price Surge Not Quite Adding Up

Sep 04
FutureChem Co.,Ltd's (KOSDAQ:220100) 29% Share Price Surge Not Quite Adding Up

FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans

Jun 13
FutureChemLtd (KOSDAQ:220100) Is In A Good Position To Deliver On Growth Plans

FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Apr 29
FutureChem Co.,Ltd (KOSDAQ:220100) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)

Feb 26
Revenues Not Telling The Story For FutureChem Co.,Ltd (KOSDAQ:220100)

Is FutureChemLtd (KOSDAQ:220100) Using Debt In A Risky Way?

Feb 05
Is FutureChemLtd (KOSDAQ:220100) Using Debt In A Risky Way?

What Percentage Of FutureChem Co.,Ltd (KOSDAQ:220100) Shares Do Insiders Own?

Dec 14
What Percentage Of FutureChem Co.,Ltd (KOSDAQ:220100) Shares Do Insiders Own?

Shareholder Returns

A220100KR Life SciencesKR Market
7D-11.5%-2.7%-5.4%
1Y76.9%32.8%-3.8%

Return vs Industry: A220100 exceeded the KR Life Sciences industry which returned 32.8% over the past year.

Return vs Market: A220100 exceeded the KR Market which returned -3.8% over the past year.

Price Volatility

Is A220100's price volatile compared to industry and market?
A220100 volatility
A220100 Average Weekly Movement12.5%
Life Sciences Industry Average Movement9.5%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A220100's share price has been volatile over the past 3 months.

Volatility Over Time: A220100's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
199970Dae-Yoon Chiwww.futurechem.co.kr

FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer’s disease.

FutureChem Co.,Ltd Fundamentals Summary

How do FutureChemLtd's earnings and revenue compare to its market cap?
A220100 fundamental statistics
Market cap₩477.29b
Earnings (TTM)-₩8.73b
Revenue (TTM)₩14.92b

32.0x

P/S Ratio

-54.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A220100 income statement (TTM)
Revenue₩14.92b
Cost of Revenue₩12.83b
Gross Profit₩2.09b
Other Expenses₩10.82b
Earnings-₩8.73b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-394.91
Gross Margin14.01%
Net Profit Margin-58.49%
Debt/Equity Ratio0%

How did A220100 perform over the long term?

See historical performance and comparison